Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 6/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17889263 | 1.00 | DUT (0.38) | DUTTBXAS1MEN1KMT2ADGAT1 | |
| SCHEMBL17897627 | 0.86 | NPC1 (0.35) | DUTDGAT1LMNACYP3A4 | |
| SCHEMBL14901265 | 0.82 | DUT (0.42) | DUTMEN1KMT2ADGAT1 | |
| SCHEMBL19810012 | 0.82 | TBXAS1 (0.39) | TBXAS1MEN1KMT2ACYP1A2USP2 | |
| SCHEMBL19810013 | 0.82 | TBXAS1 (0.39) | TBXAS1MEN1KMT2ACYP1A2USP2 | |
| SCHEMBL21517829 | 0.80 | DUT (0.36) | DUTTBXAS1DGAT1SMN1; SMN2 | |
| SCHEMBL17544453 | 0.76 | DUT (0.41) | DUTMEN1KMT2ADGAT1CYP1A2 | |
| SCHEMBL3939670 | 0.75 | TBXAS1 (0.34) | TBXAS1DGAT1 | |
| SCHEMBL4066536 | 0.74 | DUT (0.52) | DUTKMT2A | |
| SCHEMBL15758840 | 0.74 | SMN1; SMN2 (0.39) | TBXAS1MEN1KMT2ACYP1A2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3511003-B1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES (JP) | 2021-03-03 | — | — | EP | disclosed |
| EP-3511002-B1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES (JP) | 2020-08-19 | — | — | EP | disclosed |
| EP-3050877-B1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES (JP) | 2019-10-30 | — | — | EP | disclosed |
| EP-3511002-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Toray Industries, Inc. (JP) | 2019-07-17 | — | — | EP | disclosed |
| EP-3511003-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Toray Industries, Inc. (JP) | 2019-07-17 | — | — | EP | disclosed |
| US-9505740-B2 | Cyclic amine derivative and pharmaceutical use thereof | TORAY INDUSTRIES, INC. | 2016-11-29 | — | — | US | disclosed |
| EP-3050877-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Toray Industries, Inc. (JP) | 2016-08-03 | — | — | EP | disclosed |
| US-20160194302-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194302-A1 | CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | CNR2, OPRL1, CNR1 | DUT 2317/4885TBXAS1 1712/4885MEN1 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.